Neoadjuvant Therapy for HER2+ Early Breast Cancer
Neoadjuvant Therapy for HER2+ Early Breast Cancer
- A 53-year-old woman was referred to a breast surgeon after finding a mass in her left breast
- PMH: unremarkable
- FH: no history of cancer in first-degree relatives
- PE: revealed a 6 X 5-cm, non-fixed mass in the left inferior breast without skin changes or nipple discharge, and palpable lymphadenopathy in the left axilla
- ROS: clear
- Mammogram confirmed a left-sided, poorly defined spiculated mass. Ultrasound shows a 5.3-cm solid mass and enlargement of 2 left axillary nodes with thickened cortex
- Pathology results:
- Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
- ER,PR,HER2IHC 3+
- FISH,HER2copy number, 15;HER2:CEP17 ratio, 7
- Fine-needle aspiration of one left axillary lymph nodes was positive for carcinoma
- Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
- Staging: T2bN1M0
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020Podcast
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
